Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
NAGE Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Niagen Bioscience IncNASDAQ: NAGE
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 48.8% from a year ago
Total equity stood at $82.33M at the end of Q1 FY2026, up 48.8% from a year earlier and up 7.6% from the prior quarter. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Total equity amounted to 72.0% of total assets at the end of Q1 FY2026, up 4.0 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +48.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 76.53M USD
- Year-over-year change
- +66.0%
- 4-year CAGR
- +24.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.53M | +66.0% |
| FY2024 | 2024-12-31 | 46.09M | +62.0% |
| FY2023 | 2023-12-31 | 28.46M | -0.8% |
| FY2022 | 2022-12-31 | 28.67M | -9.6% |
| FY2021 | 2021-12-31 | 31.73M | — |
Total Equity vs competitors
How NAGE compares with its peers on the latest reported figures
- NAGE's Mar 2026 total equity of $82.33M is the 7th highest of the 10 companies compared; the peer median is $240.68M.
- Its year-over-year change of +48.8% is the 4th highest of 9, against a peer median of +18.3%.
- Total equity amounts to 72.0% of total assets for NAGE, versus a peer median of 79.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $480.48M | +25.3% | +34.3% | 90.5% | |
| Mar 2026 | $399.9M | +2053.8% | — | 79.2% | |
| Mar 2026 | $312.62M | -28.6% | -23.3% | 89.3% | |
| Mar 2026 | $285.63M | -60.8% | +3.0% | 91.5% | |
| Mar 2026 | $240.68M | +387.9% | +2.9% | 95.1% | |
| Mar 2026 | $205.8M | +401.7% | +27.2% | 73.9% | |
NAGENiagen Bioscience Inc | Mar 2026 | $82.33M | +48.8% | +38.7% | 72.0% |
| Mar 2026 | $27.38M | +11.4% | +84.1% | 7.6% | |
| Mar 2026 | $21.08M | -92.3% | -41.6% | 6.2% | |
| Dec 2025 | -$2.71M | — | — | 0.8% | |
| Peer median (excluding NAGE) | $240.68M | +18.3% | +3.0% | 79.2% | |
Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.02M | 20.29M | 27.17M | 44.51M | 64.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.23M | 8.48M | 5.23M | 7.77M | 9.74M |
| Inventory | 13.6M | 14.68M | 14.53M | 9.19M | 20.42M |
| Other Current Assets | 200K | 3.12M | 2.6M | 2.63M | 1.85M |
| Total Current Assets | 48.91M | 46.57M | 49.53M | 64.1M | 96.81M |
| Property, Plant & Equipment (Net) | 7.36M | 6.32M | 4.54M | 3.45M | 3.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 857K | 671K | 510K | 359K | 5.66M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 723K | 497K | 383K | 368K | 425K |
| Total Non-current Assets | 8.94M | 7.49M | 5.43M | 4.18M | 9.6M |
| Total Assets | 57.84M | 54.06M | 54.96M | 68.28M | 106.41M |
| Account Payables | 10.42M | 9.68M | 10.23M | 8.53M | 10.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 161K | 157K | 195K | 611K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 8.12M |
| Total Current Liabilities | 17.61M | 17.87M | 20.62M | 17.95M | 19.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 4.35M | 3.96M | 3.31M | 2.58M | 2.67M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 5.47M |
| Total Non-current Liabilities | 8.5M | 7.52M | 5.89M | 4.24M | 9.95M |
| Total Liabilities | 26.11M | 25.39M | 26.51M | 22.18M | 29.87M |
| Common Stock | 68K | 74K | 75K | 77K | 79K |
| Retained Earnings | (168.95M) | (185.49M) | (190.46M) | (181.91M) | (164.53M) |
| Accumulated OCI | (2K) | (3K) | (4K) | (4K) | (9K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 31.73M | 28.67M | 28.46M | 46.09M | 76.53M |
| Total Debt | 4.7M | 4.26M | 3.28M | 2.65M | 2.82M |
| Net Debt | (23.32M) | (16.03M) | (23.9M) | (41.86M) | (61.97M) |
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.